383 related articles for article (PubMed ID: 27696232)
1. Correlation of BRAF mutation and SUV
Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between
Chang JW; Park KW; Heo JH; Jung SN; Liu L; Kim SM; Kwon IS; Koo BS
World J Surg; 2018 Jan; 42(1):114-122. PubMed ID: 28808756
[TBL] [Abstract][Full Text] [Related]
3. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
4. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
5. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
[TBL] [Abstract][Full Text] [Related]
6. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma.
Kim TY; Kim WB; Ryu JS; Gong G; Hong SJ; Shong YK
Laryngoscope; 2005 Jun; 115(6):1074-8. PubMed ID: 15933524
[TBL] [Abstract][Full Text] [Related]
9. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of standardized uptake values in thyroid incidentaloma discovered by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.
Sager S; Vatankulu B; Sahin OE; Cınaral F; Uslu L; Baran A; Ozturk T; Sönmezoglu K
J Cancer Res Ther; 2018; 14(5):989-993. PubMed ID: 30197336
[TBL] [Abstract][Full Text] [Related]
11. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
12. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer.
Eloy JA; Brett EM; Fatterpekar GM; Kostakoglu L; Som PM; Desai SC; Genden EM
AJNR Am J Neuroradiol; 2009 Aug; 30(7):1431-4. PubMed ID: 19342543
[TBL] [Abstract][Full Text] [Related]
13. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
[TBL] [Abstract][Full Text] [Related]
15.
Pattison DA; Bozin M; Gorelik A; Hofman MS; Hicks RJ; Skandarajah A
J Nucl Med; 2018 May; 59(5):749-755. PubMed ID: 29025986
[No Abstract] [Full Text] [Related]
16. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography.
Salvatori M; Melis L; Castaldi P; Maussier ML; Rufini V; Perotti G; Rubello D
Biomed Pharmacother; 2007 Sep; 61(8):488-93. PubMed ID: 17604940
[TBL] [Abstract][Full Text] [Related]
17. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.
Barollo S; Pennelli G; Vianello F; Watutantrige Fernando S; Negro I; Merante Boschin I; Pelizzo MR; Rugge M; Mantero F; Nacamulli D; Girelli ME; Busnardo B; Mian C
Eur J Endocrinol; 2010 Oct; 163(4):659-63. PubMed ID: 20647301
[TBL] [Abstract][Full Text] [Related]
18. Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction.
Hwang J; Shin JH; Han BK; Ko EY; Kang SS; Kim JW; Chung JH
AJR Am J Roentgenol; 2010 May; 194(5):W425-30. PubMed ID: 20410389
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of incidental thyroid nodules on 18F-fluorodeoxyglucose positron emission tomography imaging: are these significant?
Sharma SD; Jacques T; Smith S; Watters G
J Laryngol Otol; 2015 Jan; 129(1):53-6. PubMed ID: 25496842
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.
Hwang SO; Lee SW; Kang JK; Choi HH; Kim WW; Park HY; Jung JH
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):415-20. PubMed ID: 24903453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
